1446321-46-5

Basic information

• Product Name: Voxelotor
• Synonyms: 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde;GBT 440;2-Hydroxy-6-{[2-(1-isopropyl-1H-pyrazol-5-yl)-3-pyridinyl]methoxy}benzaldehyde;Hemoglobin Modulators-1;2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde;Voxelotor(GBT440, GTX011);Voxelotor
• CAS NO: 1446321-46-5
• Molecular Formula: C₁₉H₁₉N₃O₃
• Molecular Weight: 337.37246
• Product Categories: API
• Mol File: 1446321-46-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 539.2±50.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 7.67±0.10(Predicted)
• CAS DataBase Reference: Voxelotor(CAS DataBase Reference)
• NIST Chemistry Reference: Voxelotor(1446321-46-5)
• EPA Substance Registry System: Voxelotor(1446321-46-5)

Safety Data

• Hazardous Substances Data: 1446321-46-5(Hazardous Substances Data)

Usage

Description

Voxelotor is a potent allosteric effector of sickle cell hemoglobin (Hb) that increases the affinity of Hb for oxygen and inhibits its polymerization when subjected to hypoxic conditions.

Uses

Used in Pharmaceutical Industry:
Voxelotor is used as a therapeutic agent for the treatment of sickle cell disease. It works by increasing the oxygen affinity of hemoglobin, which helps to prevent the polymerization of Hb and the subsequent formation of sickle-shaped red blood cells. This can lead to improved oxygen delivery and reduced complications associated with the disease.

Upstream product

• 387-46-2 2,6-dihydroxybenzaldehyde 
• 888958-28-9 5-(methoxymethoxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 154714-19-9 5-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 2942-59-8 2-chloronicotinic acid 
• 303-07-1 2,6-Dihydroxybenzoic acid 
• 70160-46-2 1,3-bis-(1-ethoxy-ethoxy)-benzene 
• 1282518-60-8 1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 1446321-95-4 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine hydrochloride 
• 84290-49-3 2-hydroxy-6-(methoxymethoxy)benzaldehyde 
• 6751-75-3 2-bromoresorcinol 
• 79834-12-1 2,6-bis((2-methoxyethoxy)methoxy)benzaldehyde 

Relevant articles and documents

SYNTHESIS OF A SICKLE CELL DISEASE AGENT AND INTERMEDIATES THEREOF

New processes for preparing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5- yl)pyridin-3-yl)methoxy)benzaldehyde, an agent developed for the treatment of sickle cell disease, and intermediates thereof, are provided herein.

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VOXELOTOR

The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, which comprises the use of a compound of formula (I) or (I'), or a salt or solvate thereof.

PROCESS FOR SYNTHESIZING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZALDEHYDE

Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H- pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.